GHRH
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A 44-amino-acid hormone that triggers pulsatile growth hormone release, marketed via analogs for body composition, recovery, and sleep. The mechanism is well proven, and one analog has solid human trial data for cutting visceral fat, while cognitive benefits have limited controlled human evidence from GHRH analogs and organ-protection claims remain preclinical. Chronic use raises IGF-1 and injection reactions, with an unresolved tumor-growth concern. One formulation is FDA-approved; other products are unregulated.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Growth Hormone-Releasing Hormone (GHRH), also known as somatoliberin or growth hormone-releasing factor (GRF), is a 44-amino acid peptide hormone produced primarily in the arcuate nucleus of the hypothalamus. As the primary physiological stimulator of growth hormone (GH) secretion from the anterior pituitary, GHRH is the reference standard against which all GH-releasing compounds are measured. Its discovery in 1982 independently by Guillemin et al. and Rivier/Vale et al. established the neuroendocrine basis of GH regulation.
GHRH acts through the GHRH receptor (GHRHR), a G-protein coupled receptor expressed on pituitary somatotropes as well as in extrapituitary tissues including the brain, retina, immune cells, and various peripheral organs. Through the GHRHR, GHRH activates the cAMP/PKA pathway, stimulates GH gene transcription, and promotes somatotrope proliferation. Importantly, GHRH's actions extend well beyond the pituitary — it has direct neuroprotective, anti-inflammatory, wound-healing, and cell-survival functions in multiple tissues.
Native GHRH has a short circulating half-life (~7-10 minutes) due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV). This limitation led to the development of synthetic analogs including sermorelin (GHRH 1-29), CJC-1295, and tesamorelin, which have longer half-lives and are used clinically. Sermorelin was FDA-approved for pediatric GH deficiency. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. GHRH and its analogs remain the physiological gold standard for stimulating endogenous GH release in a pulsatile, regulated manner.
How it works in the body
Growth Hormone-Releasing Hormone binds to GHRH receptors on pituitary somatotroph cells, activating adenylate cyclase and increasing cAMP. This stimulates both the synthesis and pulsatile release of growth hormone. Sermorelin (GHRH 1-29) and CJC-1295 are synthetic analogs. The native 44-amino-acid peptide is the reference standard.
Research overview
GHRH has been studied extensively for over four decades, with >5,000 PubMed publications covering its endocrine, neuroprotective, and extrapituitary functions. The development of GHRH analogs represents one of the most successful translational stories in peptide therapeutics. Key research themes include: (1) Neuroendocrine regulation — GHRH is the primary physiological stimulator of pulsatile GH secretion and somatotrope development. GHRH-null and GHRHR-null animal models confirm its essential role in GH axis function. (2) Neuroprotection — GHRHR signaling in the retina and brain has demonstrated protective effects against neurodegeneration. GHRHR antagonists paradoxically show anti-inflammatory and neuroprotective properties in retinal disease models by modulating inflammatory signaling (Cen et al., Neural Regen Res 2022). (3) Extrapituitary functions — GHRH promotes wound healing, modulates immune responses, and shows anti-apoptotic effects in cardiac tissue (Kiaris et al., Trends Endocrinol Metab 2011). (4) Analog development — Sermorelin (GHRH 1-29) retains full GHRHR agonist activity. CJC-1295 has a half-life extended to ~8 days via Drug Affinity Complex (DAC) technology or albumin binding. Tesamorelin adds a trans-3-hexenoic acid modification for stability. These analogs have been tested in clinical trials for GH deficiency, aging, cognitive function, and body composition.
Who researches GHRH?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People exploring sleep quality improvement
Researched for effects on sleep architecture, circadian rhythm, or sleep quality.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching cardiovascular health
Studied for effects on heart function, blood pressure, or vascular health.
Important considerations for
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Anyone under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Those with Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Safety & interactions
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNot recommended for children outside a clinical study or an approved pediatric indication; GHRH has been studied in children with GH deficiency.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(4)
Rated by level of concern
Injection site reactions (swelling, redness, pain)
HighFDA EGRIFTA WR prescribing information, Adverse Reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Elevated IGF-1 levels with chronic use
HighFDA EGRIFTA WR prescribing information, Warnings and Precautions (Elevated IGF-1 Levels) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Fluid retention, joint pain, carpal tunnel (GH-related effects)
ModerateFDA EGRIFTA WR prescribing information, Adverse Reactions and Warnings (Fluid Retention) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Potential tumor growth stimulation in GH-sensitive cancers
TheoreticalFDA EGRIFTA WR prescribing information, Contraindications (active malignancy) and Warnings (neoplasms) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Interaction summary(8)
Rated by direction with this peptide
Insulin, sulfonylureas and other antidiabetic agents (and diabetes generally)
CautionModerateGH induces peripheral insulin resistance, so GHRH-driven GH elevation can raise fasting glucose and HbA1c and blunt the effect of glucose-lowering therapy — the tesamorelin label carries a 'Glucose Intolerance or Diabetes Mellitus' warning directing glucose and HbA1c monitoring, making this the most clinically real interaction in the class. Note that in the JAMA 2014 randomized trial fasting glucose rose at 2 weeks but the 6-month change was not significant, so magnitude in non-diabetic patients appears modest.
FDA EGRIFTA WR prescribing information, Warnings and Precautions (Glucose Intolerance or Diabetes Mellitus) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75); PMID 25038357
Glucocorticoids / corticosteroid replacement (prednisone, hydrocortisone, cortisone)
CautionModerateThe tesamorelin label's own Drug Interactions section states that GH inhibits 11-beta-hydroxysteroid dehydrogenase type 1 and reduces conversion of cortisone to cortisol, so patients on glucocorticoid replacement for hypoadrenalism may need higher replacement or stress-dose glucocorticoids, and previously unrecognized central adrenal insufficiency can be unmasked. The converse direction (pharmacologic glucocorticoids suppressing the GH response to GHRH) comes from neuroendocrine stimulation-test literature, not the label.
FDA EGRIFTA WR prescribing information, Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Somatostatin and somatostatin analogs (octreotide, lanreotide, pasireotide)
CautionModerateDirect pharmacologic antagonism at the somatotroph — somatostatin is the physiological brake on GHRH-stimulated GH release, so somatostatin analogs largely abolish the GH response to GHRH and render GHRH therapy or GHRH stimulation testing uninterpretable. The consequence is loss of efficacy and invalid test results, not toxicity or a dangerous reaction.
Established human neuroendocrine pharmacology; basis of the GHRH-arginine and GHRH stimulation test protocols
GH secretagogue receptor agonists (ipamorelin, GHRP-2/GHRP-6, hexarelin, ghrelin, MK-677)
SynergisticModerateSupra-additive rather than additive in humans — GHRH acts via GHRH-R/cAMP while ghrelin-mimetics act via GHS-R1a and suppress somatostatin tone, and co-administration produces a markedly larger GH pulse than either alone. This is established from acute combined stimulation testing; there are no controlled human data on chronic co-administration, so the practical inference is that using them together amplifies both the intended effect and the IGF-1, fluid-retention and glycemic risks.
Human GH-stimulation-test literature (GHRH + GHRP-6/GHRP-2 combined testing)
Pyridostigmine and other cholinesterase inhibitors
SynergisticLowCholinergic enhancement suppresses hypothalamic somatostatin tone and potentiates the GH response to GHRH in humans — a reproducible acute neuroendocrine finding used experimentally to restore blunted GHRH responses in aging and obesity; conversely anticholinergics such as atropine blunt the GHRH response. Evidence is from single-dose stimulation testing only; no chronic-therapy data exist.
Human GHRH + pyridostigmine stimulation-test literature (Ghigo et al. and subsequent replications)
Oral estrogen / combined oral contraceptives
CautionLowFirst-pass hepatic estrogen induces GH resistance at the liver and attenuates the IGF-1 rise for a given GH signal, so oral (but not transdermal) estrogen users may see reduced downstream benefit and misleading IGF-1 monitoring values. Established from GH-replacement dosing studies; extrapolated to GHRH analogs, which have not been studied for this specifically.
GH-replacement literature on oral vs transdermal estrogen effects on IGF-1 generation
Levothyroxine / thyroid hormone status
CautionLowGH increases peripheral T4-to-T3 conversion and can unmask previously undiagnosed central hypothyroidism or reduce free T4, so thyroid function warrants rechecking after starting therapy; conversely untreated hypothyroidism blunts the GH response to GHRH. The tesamorelin label contains no thyroid or levothyroxine interaction — this is extrapolated from somatropin/GH-replacement data. It is relevant mainly because tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis.
Somatropin/GH-replacement literature on the thyroid axis (not stated in the tesamorelin label)
CYP450 substrates with narrow therapeutic index (e.g. ciclosporin, anticonvulsants, corticosteroids, sex steroids)
CautionTheoreticalThe tesamorelin label's Drug Interactions section states that GH may alter the clearance of drugs metabolized by cytochrome P450, specifically naming corticosteroids, sex steroids, anticonvulsants and cyclosporine, and advises monitoring. No specific interaction has been quantified in dedicated human studies of tesamorelin.
FDA EGRIFTA WR prescribing information, Drug Interactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Known risks(4)
Injection site reactions (swelling, redness, pain)
MildCommon with subcutaneous GHRH analog injections. Reported in 10-20% of participants in tesamorelin clinical trials. Generally mild and self-limiting.
Elevated IGF-1 levels with chronic use
ModerateSustained GHRH agonist therapy can elevate IGF-1 levels. Chronically elevated IGF-1 has been associated with increased cancer risk in epidemiological studies. IGF-1 monitoring is recommended during long-term use.
Fluid retention, joint pain, carpal tunnel (GH-related effects)
Mild to ModerateBy stimulating GH release, GHRH analogs can cause the same side effects as exogenous GH: fluid retention, arthralgia, and peripheral edema. These are generally dose-dependent and reversible.
Potential tumor growth stimulation in GH-sensitive cancers
Theoretical / PrecautionaryGH and IGF-1 can promote growth of certain tumors. GHRH analogs are contraindicated in patients with active malignancy. Conversely, GHRHR antagonists are being investigated as anti-cancer agents.
Drug interactions(4)
Exogenous growth hormone (somatropin)
Co-administration may produce supraphysiological GH levels. GHRH analogs are generally used as an alternative to exogenous GH, not in combination. Negative feedback via IGF-1 may blunt GHRH's effect during concurrent GH use.
Somatostatin analogs (octreotide, lanreotide)
Somatostatin and its analogs directly oppose GHRH's stimulatory effect on GH release. Co-administration would attenuate or abolish GHRH's primary action.
GH secretagogues (GHRP-6, ipamorelin, MK-677)
GHRH and ghrelin-receptor agonists have synergistic effects on GH release when combined. This can produce supraphysiological GH pulses. Combination use is sometimes explored in anti-aging contexts but increases risk of GH-related side effects.
Glucocorticoids (prednisone, dexamethasone)
Chronic glucocorticoid use suppresses GH secretion and may blunt the response to GHRH. Conversely, GHRH treatment may partially counteract glucocorticoid-induced GH deficiency.
Research & benefits
Evidence base
- Evidence Level
- Strong Evidence (analogs FDA-approved)
- Total Studies
- 5000
- Human Participants
- 5000
GHRH analogs have a robust clinical evidence base. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy based on Phase 3 trials showing significant reduction in visceral adipose tissue. Sermorelin was FDA-approved for pediatric GH deficiency (now discontinued in US). Clinical trials have also explored GHRH analogs for age-related GH decline, cognitive function in older adults, and sleep improvement. Native GHRH is used clinically as a diagnostic agent for GH deficiency. The overall evidence base for GHRH-system therapeutics is substantial with thousands of human participants across multiple indications.
Researched for(6)
Rated by confidence in the evidence
Physiological stimulation of endogenous GH release in a pulsatile, regulated manner
MediumNative GHRH studies and tesamorelin's FDA label confirm pulsatile, not flat, GH release.
FDA EGRIFTA WR (tesamorelin, a GHRH analog) prescribing information, Clinical Pharmacology, Section 12.1 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75); PMID 8772566 (Marshall et al., J Clin Endocrinol Metab 1996 — direct human trial comparing episodic vs continuous native GHRH administration, showing episodic dosing produces greater GH elevation and slow-wave sleep promotion)
Improved body composition (reduced visceral fat) via tesamorelin in HIV lipodystrophy
HighConfirmed in phase 3 RCTs and a 2026 meta-analysis; benefit reverses on stopping.
PMID 25038357 (Stanley et al., JAMA 2014;312:380-9, NCT01263717); PMID 41545261 (meta-analysis of 5 RCTs, Obes Res Clin Pract 2026); FDA EGRIFTA WR label, Clinical Studies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)
Neuroprotective and anti-inflammatory effects in retinal degeneration models
LowRodent studies only; synthetic analogs protected retinal cells, no human trials exist.
PMID 34244423 (PNAS 2021;118(28), MR-409, optic nerve injury, rats); PMC5740669 (PNAS 2017, GHRH agonists in early experimental diabetic retinopathy, rats)
Promotion of deep (slow-wave) sleep and sleep quality improvement
LowSmall human studies mixed; a later trial found no slow-wave sleep effect.
PMID 8476038 (Am J Physiol 1993, sleep-promoting effects of GHRH in normal men); PMID 8772566 (J Clin Endocrinol Metab 1996, episodic > continuous); PMID 15538933 (Eur J Endocrinol 2004 — negative for SWS: GHRH-R blockade suppressed GH but did not reduce SWS)
Potential cognitive benefits in aging via restoration of GH/IGF-1 axis
MediumOne randomized trial improved executive function in older adults, unreplicated since.
PMID 22869065 (Baker et al., Arch Neurol 2012;69:1420-9)
Cardioprotective effects — anti-apoptotic signaling in cardiac tissue
LowAnimal models only; GHRH analogs reduced heart attack damage, no human trials yet.
PMID 20133784 (Kanashiro-Takeuchi et al., PNAS 2010, cardioprotective effects of GHRH agonist after MI); PMC4260571 (PNAS 2014;111(48), GHRH agonists and cardiac stem cell self-renewal); PMID 25827134 (J Am Heart Assoc 2015, swine)
Benefits(6)
Physiological stimulation of endogenous GH release in a pulsatile, regulated manner
Multiple clinical studies with GHRH and analogs; Thorner et al., J Clin Endocrinol Metab 1985
Improved body composition (reduced visceral fat) via tesamorelin in HIV lipodystrophy
Falutz et al., NEJM 2007 (Phase 3, n=412); FDA approval basis for Egrifta
Neuroprotective and anti-inflammatory effects in retinal degeneration models
Cen et al., Neural Regen Res 2022 (review of GHRHR in retinal neuroprotection)
Promotion of deep (slow-wave) sleep and sleep quality improvement
Steiger et al., Neuroendocrinology 1992; Perras et al., Psychoneuroendocrinology 1999
Potential cognitive benefits in aging via restoration of GH/IGF-1 axis
Vitiello et al., Neurobiology of Aging 2006 (GHRH treatment in 89 healthy older adults; PMID 16399214)
Cardioprotective effects — anti-apoptotic signaling in cardiac tissue
Kiaris et al., Trends Endocrinol Metab 2011 (review of extrapituitary GHRH functions)
Key studies(3)
Schally AV, et al.
Reviews in Endocrine and Metabolic Disorders
2024
Comprehensive review of GHRH analog development from the native 44-amino acid peptide to clinically used analogs. Covers sermorelin (GHRH 1-29), CJC-1295, tesamorelin, and investigational compounds. Discusses structure-activity relationships, pharmacokinetics, and clinical applications.
Cen LP, Ng TK, Chu WK, Pang CP.
Neural Regeneration Research
2022
Reviews GHRHR expression and signaling in retinal and neural tissues. GHRHR antagonists show anti-inflammatory and neuroprotective effects in retinal disease models. GHRHR signaling modulates inflammatory pathways independent of GH/IGF-1 axis effects.
Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV.
Trends in Endocrinology & Metabolism
2011
Establishes GHRH as a pleiotropic hormone with functions far beyond pituitary GH release. Describes extrapituitary GHRH production and direct actions in cardiac tissue, immune cells, wound healing, and cancer. Demonstrates that GHRH has autocrine/paracrine roles independent of the GH axis.
Regulation & availability
Why researchers look at it
GHRH is the body's own master switch for growth hormone release, making it the physiological gold standard for restoring GH secretion in a natural, pulsatile pattern. Its analogs like tesamorelin have proven clinical utility, and emerging research reveals direct neuroprotective and anti-inflammatory effects beyond the GH axis.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Native GHRH: Used as diagnostic agent; not FDA-approved for therapeutic use. Tesamorelin (Egrifta): FDA-approved (2010) for HIV-associated lipodystrophy. Sermorelin: Previously FDA-approved for pediatric GH deficiency; approval withdrawn by manufacturer (not for safety reasons). CJC-1295: Not FDA-approved; investigational. GHRH and analogs are the reference standard for physiological GH stimulation.
- WADA status
- GHRH and all its analogs are PROHIBITED by WADA under the 2026 Prohibited List. They are classified under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. Specifically, GHRH and its analogs (including CJC-1295, sermorelin, and tesamorelin) are prohibited both in-competition and out-of-competition. This is because they stimulate GH secretion, which enhances muscle growth and recovery.
- Prescribability
- Analogs Only — Sermorelin (discontinued in US), Tesamorelin (FDA-approved for HIV lipodystrophy). Native GHRH not prescribed.
- Availability
- Clinically used analogs include: Tesamorelin (Egrifta) — FDA-approved and commercially available for HIV lipodystrophy by prescription. Sermorelin — previously FDA-approved for pediatric GH deficiency; now available through compounding pharmacies in the US but was subject to FDA scrutiny as of 2023. GHRH is also used as a diagnostic agent (GHRH stimulation test) in endocrinology.
International status
US
Native GHRH not marketed; analog sermorelin previously FDA-approved (withdrawn for commercial reasons); tesamorelin FDA-approved for HIV lipodystrophy
Worldwide
WADA prohibited; analogs available by prescription in various countries
Regulatory timeline(8)
- 1982GHRH (GRF) isolated and characterized by Guillemin and Rivier
- 1990Sermorelin (GHRH 1-29, Geref) approved by FDA for pediatric GH deficiency diagnosis
- 1997Sermorelin approved for therapeutic GH deficiency treatment
- 2008Sermorelin withdrawn from US market by manufacturer (not for safety reasons)
- 2010Tesamorelin (Egrifta) approved by FDA for HIV-associated lipodystrophy
- 2011Kiaris et al. publish landmark review of GHRH extrapituitary functions
- 2022GHRHR neuroprotective signaling reviewed in retinal degeneration context
- 2024Comprehensive review of GHRH analog development published by Schally group
Sources & FAQs
Research sources(4)
Frequently asked questions(4)
How does GHRH differ from its analogs like sermorelin and CJC-1295?
Native GHRH is a 44-amino acid peptide with a half-life of only 7-10 minutes. Sermorelin (GHRH 1-29) contains the first 29 amino acids — the minimum fragment needed for full receptor activation — with a slightly longer half-life. CJC-1295 further modifies the sequence for DPP-IV resistance and can be conjugated with Drug Affinity Complex (DAC) technology for a half-life of ~8 days. Tesamorelin adds a trans-3-hexenoic acid group for enhanced stability.
Why is GHRH considered the 'reference standard' for GH secretagogues?
GHRH is the body's own signal for GH release. Unlike synthetic GH secretagogues (GHRP-6, ipamorelin) that work through the ghrelin receptor, GHRH acts through its own dedicated receptor (GHRHR) on pituitary somatotropes. This produces a physiological, pulsatile GH release pattern rather than the supraphysiological spikes seen with exogenous GH injection or ghrelin mimetics.
Does GHRH have effects beyond growth hormone release?
Yes. GHRH and its receptor are expressed in many tissues outside the pituitary, including the brain, retina, heart, immune cells, and GI tract. GHRH has direct neuroprotective, anti-inflammatory, cardioprotective, and wound-healing effects that appear independent of GH/IGF-1. This 'not only a neurohormone' concept has expanded the therapeutic landscape for GHRH-based compounds.
Is tesamorelin the same as GHRH?
Tesamorelin is a stabilized analog of GHRH, not the identical native peptide. It consists of the full GHRH(1-44) sequence with a trans-3-hexenoic acid group added to the N-terminus, which improves stability and extends half-life. It acts through the same GHRHR receptor and stimulates the same GH release pathway.